• DXC Assure Smart Apps provide modular, pre-built, AI-driven workflows that deliver business benefits in 12 weeks or less
• Together with customers, DXC created and introduced new Claims Assistant, Engagement Assistant, and Underwriter Assistant apps at DXC Connect Insurance Executive Forum
• The apps help insurers accelerate digital transformation, reducing manual processes by 30-40% and cutting cycle process times by approximately 30%

ASHBURN, Va., April 9, 2026 /PRNewswire/ — DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced new Assure Smart Apps built on ServiceNow, recently launched at the DXC Connect Insurance Executive Forum in March 2026. Assure Smart Apps combine DXC’s deep insurance expertise with ServiceNow’s agentic AI and workflow technology to deliver modular, outcome-driven solutions for insurers. Each app is orchestrated through DXC’s Assure Platform to accelerate targeted transformation.

DXC Connect Insurance Executive Forum, March 2026

Insurers today face mounting pressure from evolving customer expectations, regulatory complexity, and increased competition while operating across fragmented legacy systems and siloed data. Addressing these challenges typically requires large, multi-year transformation programs that can take years to deliver results.

Assure Smart Apps are designed to help insurers modernize incrementally, without disrupting core systems or requiring extensive time and resource investments. These modular, AI-driven workflow applications are pre-integrated with core policy solutions to deliver measurable outcomes in 12 weeks or less. Insurers can reduce manual processes by 30–40% and cut cycle times by up to 30%, enabling faster progress toward transformation goals.

“By bringing together ServiceNow’s agentic AI and workflow technology and DXC’s deep insurance industry expertise, we’re redefining what’s possible in insurance operations,” said Michael Park, SVP, Global Partnerships and Channels at ServiceNow. “Together, we’re helping carriers accelerate transformation, delivering greater agility and speed across every process.”

At DXC Connect Insurance Executive Forum, DXC’s annual insurance customer community event, three new Assure Smart Apps were introduced:

• Claims Assistant unifies the end-to-end claims lifecycle, embedding compliance and audit readiness while eliminating system hopping and manual reconciliation. It can reduce claim cycle times by up to 35%, enabling faster payouts and improved policyholder experiences.
• Engagement Assistant modernizes customer engagement across voice, digital, and back-office channels by orchestrating digital agents, human agents, and analytics. It automates servicing, boosts agent productivity, and delivers real-time sentiment and compliance insights—improving customer experience by 5–15%.
• Underwriter Assistant provides a concierge underwriting experience by automating submission intake, prioritizing work, and guiding decisions through a unified, explainable workbench—without disrupting existing policy systems.

DXC also showcased the Assure Smart App Studio, a collaborative innovation environment, where customers contributed ideas for future Smart Apps. During the event, DXC engineers rapidly prototyped new AI agents overnight and demonstrated them on day two—highlighting how quickly organizations can move from ideation to execution with AI-powered innovation.

“The inspiration for Smart Apps was meeting our customers where they are and creating a pathway for incremental transformation,” said Ray August, President, DXC Insurance Software and Business Process Services. “We are proud to innovate alongside our customers to build solutions that advance their technology infrastructure without disrupting operations. We are helping them modernize at their own pace while delivering tangible business results.”

With more than 40 years of industry expertise, DXC is a trusted partner to 21 of the top 25 insurers worldwide. As a leading provider of core insurance systems, DXC drives AI-powered innovation to improve speed to market, operational efficiency, and customer experience.
To learn more, visit www.dxc.com/assure-smart-apps.

About DXC Technology 

DXC Technology (NYSE: DXC) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change with speed. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world’s most complex technology estates. Learn more on dxc.com.

DUBAI, UAE, April 9, 2026 /PRNewswire/ — Blockchain for Good Alliance (BGA), the global non-profit initiative founded by Bybit, dedicated to leveraging blockchain for societal impact, convened global leaders, policymakers, and industry stakeholders at an exclusive private gathering held at the House of Lords in the Palace of Westminster, London.

The first of BGA’s new initiatives, the Impact Leaders’ Summits, the gathering marked a significant milestone in BGA’s expansion into the UK ecosystem, bringing together senior figures across government, finance, technology, and international organisations to discuss the evolving role of blockchain in shaping transparent, accountable, and inclusive systems.

The evening was formally opened by John David Beckett Taylor, Baron Taylor of Warwick, with distinguished attendees including Kulveer Singh Ranger, Baron Ranger of Northwood, Manzila Pola Uddin, Baroness Mazila Uddin and former UK Member of Parliament Lisa Cameron, and key industry leaders including Helen Liu, Founder of BGA, founder of AB Finance, and former Co-CEO of Bybit.

Throughout the evening, speakers highlighted the importance of collaboration between public and private sectors in unlocking the full potential of blockchain technology, and a central highlight was BGA’s first impact report, The State of Blockchain for Good: A View from the Alliance, authored by Glenn Tan, Director of Global Affairs at BGA.

“‘Purpose over profit’ was a phrase noted by BGA in their report that caught my attention,” commented Lord Taylor in his opening speech. “The report outlines a clear shift within the blockchain industry, and organizations like BGA play a pivotal role in ensuring that technology does not only serve financial gain, but also the betterment of societies.”

“As blockchain integrates into essential digital infrastructure, we must ensure these systems are built with a focus on collective benefit,” said Lord Ranger, in the Summit’s closing remarks. “I congratulate BGA on their publication, one that isn’t just about technical milestones but a testament to how blockchain technology is already implemented and deployed in the world, and already changing lives.”

Helen Liu, Founder of BGA, underscored the Alliance’s role in convening global stakeholders and supporting projects that demonstrate both impact and scalability, noting that the next phase of blockchain adoption will be driven by solutions that are commercially viable and capable of operating at scale.

“The discussions tonight reinforced key principles championed by BGA,” said Liu. “Initiatives focused on public good are not at odds with commercial success but rather that sustainable impact is achieved when solutions are both economically viable and widely adoptable.”

Strengthening the UK as a Hub for Responsible Innovation

The event also highlighted the United Kingdom’s growing position as a leading centre for financial innovation and regulatory leadership. With growing engagement between policymakers and blockchain ecosystems, the UK continues to play a pivotal role in shaping frameworks that balance innovation with accountability.

BGA’s presence in the UK signals its commitment to contributing to this ecosystem by connecting global builders, institutional partners, and capital to accelerate the deployment of impactful blockchain solutions.

Looking Ahead

“The BGA Impact Leaders Summit is a new initiative of the Alliance in our global strategy,” said Glenn Tan, Director of Global Affairs at BGA. “We look forward to convening future Summits across different regions to continue fostering global dialogue at the intersection of technology, governance, and impact capital.”

As blockchain continues to mature, BGA remains focused on advancing initiatives that move beyond experimentation and toward scalable, real-world implementation, working alongside governments, international organisations, and industry leaders worldwide.

#Bybit / #TheCryptoArk / #BGA

Helen Liu addresses guests during the Blockchain for Good Alliance Impact Leaders’ Summit at the UK House of Lords, sharing insights on advancing blockchain for societal impact.

About Blockchain for Good Alliance (BGA)

The Blockchain for Good Alliance (BGA) is a global nonprofit initiative founded by Bybit, dedicated to advancing blockchain as a tool to address real-world problems. By convening leaders, innovators, and organisations from across the blockchain industry, BGA seeks to drive innovation, collaboration and action toward a more sustainable and equitable world.

For more information:
Email: hello@chainforgood.org
Website: www.chainforgood.org
Twitter: www.x.com/chainforgood
LinkedIn: https://www.linkedin.com/company/blockchainforgoodalliance/

BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ — Gan & Lee Pharmaceuticals (hereinafter referred to as “Gan & Lee”, SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and developed by Gan & Lee.

Strategic Alliance: By Leveraging JW’s Strengths in R&D and Commercialization in South Korea, Gan & Lee Will Establish a Strong Commercial Footprint in South Korea’s High-Potential Metabolic Disease Market 

Under the terms of the agreement, JW Pharmaceutical will be granted the exclusive rights to develop and commercialize Bofanglutide Injection in South Korea. Gan & Lee Pharmaceuticals will receive a one-time, non-refundable upfront payment of USD 5 million. Additionally, Gan & Lee is eligible to receive milestone payments totaling USD 76.1 million, contingent upon research and development progress, regulatory approvals, and commercialization achievements. Following the product’s commercial launch, Gan & Lee will also receive tiered royalties based on net sales. The total potential transaction value reaches up to USD 81.1 million (excluding royalties).

This collaboration marks the third overseas out-licensing deal for Gan & Lee’s Bofanglutide Injection, following previous partnerships in Latin America and India. According to data from Grand View Research, the GLP-1RA market in the Asia-Pacific region reached USD 5.47 billion in 2025 and is projected to grow to USD 16.95 billion by 2033, representing a compound annual growth rate (CAGR) of 14% ^[1], making it one of the fastest-growing regions globally. Currently, the treatment penetration rate of GLP-1 drugs remains extremely low, indicating massive growth potential. As a mature market in the Asia-Pacific region, South Korea’s GLP-1RA market size reached USD 526 million in 2025 and is expected to increase to USD 1.6 billion by 2033 ^[2]. With its high acceptance of innovative drugs and strong patient purchasing power, the South Korean market has become a strategic foothold for multinational pharmaceutical companies entering East Asia. This collaboration marks another key step in the rapid global expansion of Gan & Lee’s differentiated bi–weekly GLP–1RA, Bofanglutide.

Steady Progress in Global Phase III Clinical Trials; Bi-weekly Dosing Regimen Significantly Enhances Patient Compliance

Currently, as the world’s first bi-weekly GLP-1RA to enter Phase III clinical research, Bofanglutide has advanced into the critical Phase III stage of its global development for three proposed indications: obesity/overweight, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA). Existing clinical data demonstrate that Bofanglutide can effectively reduce body weight and blood glucose levels while comprehensively improving other metabolic parameters, yielding overall metabolic benefits. Its safety and tolerability profiles are consistent with other GLP-1RA class therapies. The bi-weekly dosing regimen further reduces the annual number of injections by 50% compared to mainstream once-weekly GLP-1RAs. This is anticipated to substantially boost patient adherence, offering a more convenient treatment option for the long-term, effective management of metabolic diseases.

As the global burden of metabolic diseases continues to rise, GLP-1 therapies are encountering tremendous market opportunities. South Korea, as one of the world’s key pharmaceutical markets, exhibits a robust demand for innovative diabetes  and weight-loss therapies. This collaboration will effectively address the clinical and commercial needs of the South Korean market for highly efficacious and convenient treatment regimens.

“This partnership with JW Pharmaceutical marks another pivotal step in the globalization strategy for Bofanglutide,” stated Dr. Zhi Li, Chief Business  Officer of Gan & Lee Pharmaceuticals. “GLP-1 therapies are reshaping the global treatment landscape for metabolic diseases. The convenience of Bofanglutide’s bi-weekly dosing and its compelling clinical benefits will help address the unmet medical needs of South Korean patients. With over 80 years of experience, JW brings deep development and commercial expertise in metabolic diseases—a key factor in our decision to partner with JW.”

Young-sub Shin, CEO of JW Pharmaceutical, commented: “This agreement represents a significant milestone in expanding our product portfolio within the rapidly growing therapeutic area of metabolic diseases, particularly diabetes and obesity. JW Pharmaceutical will leverage its established expertise in clinical development and regulatory execution, remaining committed to advancing the development and commercialization of Gan & Lee’s Bofanglutide in South Korea, thereby bringing innovative treatment options to South Korean patients.”

About Bofanglutide

Bofanglutide Injection (GZR18), independently developed by Gan & Lee Pharmaceuticals, is a bi-weekly administered GLP-1RA designed for the treatment of obesity/overweight, type 2 diabetes mellitus (T2DM), and other metabolic diseases. Clinical research data indicates that Bofanglutide can effectively reduce body weight and lower blood glucose levels, while comprehensively improving other metabolic parameters. With safety and tolerability profiles consistent with the GLP-1RA class of drugs, it is poised to potentially become the world’s first commercially available bi-weekly GLP-1RA. Currently, the global development of Bofanglutide Injection has entered the Phase III clinical research stage.

About JW Pharmaceutical

Founded in 1945, JW Pharmaceutical Corporation has been a leader in Korea’s therapeutic pharmaceutical market, guided by its founding principles of respect for life and a spirit of challenge. With a robust portfolio of original medicines, JW Pharmaceutical has focused on innovative drug discovery and development since the establishment of its Central Research Institute in 1983 and the C&C Research Laboratories in 1992. Through advanced research technologies, including its AI-based drug discovery and development platform, JWave, the company has built a strong pipeline in areas such as oncology, immunology, and regenerative medicine. JW Pharmaceutical also actively pursues diverse research initiatives aligned with global trends through open innovation. JW Pharmaceutical Corporation is listed on the Korea Exchange under the ticker “001060.”

References:

1. Grand View Research. (2026). Asia Pacific GLP-1 Receptor Agonist Market Size & Outlook, 2033 (Horizon Databook), https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/asia-pacific
2. Grand View Research. (2026). South Korea GLP-1 Receptor Agonist Market Size & Outlook, 2033, https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/south-korea
3. Gan & Lee Pharmaceuticals Officially Initiates GRADUAL-3, China’s First Phase III Clinical Trial for Weight Management with a Once-Monthly GLP-1RA. [Press Release], https://mp.weixin.qq.com/s/wHWm0CPGRfwTK6iTcjHwfA
4. From “Follower” to “Leader”: Domestic Bi-weekly Bofanglutide Debuts at ADA, Ushering in “China Time” for Diabetes Treatment. [Press Release], https://mp.weixin.qq.com/s/6p_ou6d4DmopTennpKxbCg
5. Gan & Lee Pharmaceuticals’ Bofanglutide (GZR18) Injection Approved for Clinical Trial of New Indication: Moderate to Severe Obstructive Sleep Apnea in Obese Adult Patients. [Press Release], https://mp.weixin.qq.com/s/AT_v7pctR5CxaX7BgHcN5A
6. Gan & Lee Pharmaceuticals Enters into an Exclusive Commercial Agreement with Renowned Latin American Pharmaceutical Company PC for Bofanglutide. [Press Release], https://mp.weixin.qq.com/s/lTMxrLIb6ppZ76O9o5pGMw
7. Gan & Lee Pharmaceuticals Enters into a Partnership with Leading Indian Pharmaceutical Company Lupin. [Press Release], https://mp.weixin.qq.com/s/w44yByJ68buuyXSxwItFhg

About Gan & Lee

Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company and the first in China to master industrial-scale manufacturing technologies for recombinant insulin analogs. The Company has established a comprehensive insulin research and development pipeline.

Currently, Gan & Lee offers six core insulin products, including five insulin analogs: insulin glargine injection (Basalin^®; EU brand name Ondibta^®), insulin lispro injection (Prandilin^®; EU brand name: Bysumlog^®), insulin aspart injection (Rapilin^®; EU brand name: Dazparda^®), premixed insulin lispro protamine suspension injection (25R) (Prandilin^®25), and insulin aspart 30 injection (Rapilin^®30); as well as one human insulin product, premixed human insulin protamine suspension injection (30R) (Similin^®30), together with related delivery devices. These products cover the long-acting, rapid-acting, and premixed insulins.

In China’s second round of national volume-based procurement for insulin, Gan & Lee ranked first among selected companies by contracted volume for insulin analogs, further strengthening its domestic market position. In parallel, the Company continues to advance its international expansion. Insulin glargine injection has received marketing authorization from the European Commission (EC), while for insulin lispro injection and insulin aspart injection, it has received the positive opinion from CHMP of EMA. Gan & Lee is steadily progressing toward its goal of becoming a key global participant in the field of metabolic diseases.

Looking forward, Gan & Lee is committed to achieving comprehensive coverage across the diabetes treatment landscape and further enhancing its competitive position in this therapeutic area. The Company will also actively pursue the development of innovative chemical drugs and biologics, with a strategic focus on metabolic diseases, cardiovascular diseases, and other therapeutic areas.

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, April 9, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on April 9th

• ICE Brent Crude oil resumes its gain Thursday morning after falling below $95 a barrel Wednesday on the two-week ceasefire between the U.S. and Iran.
• Shares of Meta Platforms, a top NYSX holding, are set to add to yesterday’s 6.5% rally after its ‘Muse Spark’ AI model release.
• The fourth annual NYSE Sustainability Leaders Summit takes place this afternoon, convening executives at 11 Wall Street.

Opening Bell
Oliver Wyman Forum (NYSE: MRSH) rings the NYSE Opening Bell

Closing Bell
MNTN (NYSE: MNTN) rings the NYSE Closing Bell

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Delivering technical clarity, financial calculus, and courtroom credibility in AI-related litigation.

NEW YORK, April 9, 2026 /PRNewswire/ — J.S. Held announced today the expansion of its integrated capabilities to support clients addressing the legal, technical, and financial complexities of artificial intelligence (AI)-related disputes. This expansion comes as the firm’s Q1 AI Disputes Monitor projects a 50% rise in AI-related case filings, underscoring the growing need for specialized expertise in this fast-evolving and complex area of litigation. 

AI disputes center on the development, deployment, or impact of artificial intelligence and differ fundamentally from traditional litigation. These matters involve systems that are simultaneously technical artifacts, economic assets, and evidentiary tools, each dimension influencing the others. Unlike conventional matters where questions can be addressed in isolation, AI disputes require a unified multidisciplinary approach. J.S. Held connects technical insight, financial analysis, and litigation experience to provide comprehensive support across all phases of dispute resolution.

Why AI Disputes Demand Integrated Expertise

J.S. Held offers integrated expertise to address the unique challenges of AI-related litigation. This approach is essential due to the complex, interdependent nature of AI systems. These matters often require:

• Technical clarity to explain how AI systems behave, including digital forensics, model versioning, and data provenance.
• Financial calculus to quantify economic damages, assess market impact, and evaluate intellectual property value.
• Courtroom credibility to present findings in a manner that withstands legal scrutiny across jurisdictions.

“AI disputes uniquely require integrated expertise because AI systems exist at the intersection of three inseparable domains,” said JP Brennan, Senior Managing Director at J.S. Held. “Our work focuses on helping clients understand and explain how these systems operate in real-world contexts. We apply structured forensic methods—such as system log reconstruction, prompt replay, and model version analysis—to support investigations and testimony.”

J.S. Held experts are known for a “teaching, not telling” approach to expert testimony. Rather than simply offering an opinion, they break down complex information into clear, logical explanations that judges and juries can easily follow. “AI-related disputes increasingly require a combination of financial expertise, technical understanding, and legal analysis that is clearly communicated and able to withstand courtroom scrutiny,” said James E. Malackowski, CPA, CLP, Chief Intellectual Property Officer at J.S. Held and Senior Managing Director at Ocean Tomo. “We provide economic damages assessments, intellectual property valuation, and market impact analysis that help judges and juries evaluate questions of fair use, licensing, and commercial harm.”

Experience with AI Systems Across Sectors

J.S. Held’s work with AI systems spans multiple industries and use cases. Recent engagements include: 

• AI Risk and Governance: Designed and implemented an AI risk and controls framework for a property and casualty insurer, improving transparency, regulatory readiness, and model oversight.
• Vendor Ecosystem Advisory: Conducted vendor benchmarking and risk assessments for third-party AI tools at a fintech company, reducing costs, improving governance, and mitigating vendor lock-in.
• Model Validation: Independently assessed a machine-learning fraud detection model for a digital payments platform, identifying performance and bias risks and delivering recommendations to strengthen reliability and compliance.

These engagements reflect J.S. Held’s ability to scale technical insight and support clients managing the operational and regulatory implications of AI adoption and related litigation risk.

AI Copyright Litigation – Thomson Reuters v. Ross Intelligence

J.S. Held’s role in Thomson Reuters Enterprise Centre GmbH and West Publishing Corp. v. Ross Intelligence Inc. (U.S. District Court, D. Delaware, Case No. 1:20-cv-613-SB) demonstrates the firm’s ability to support litigation at the intersection of AI and intellectual property.

James E. Malackowski was engaged as a financial damages expert to assess the fourth fair use factor (market impact) in this matter involving the use of proprietary legal research content to train a generative AI system. The engagement addressed questions of licensing markets for training data, economic substitution, and the valuation of editorial content in AI development.

Executive Perspective – Scaling with Purpose

“As AI technologies continue to evolve, our clients face increasingly complex disputes that demand more than traditional expertise,” said Lee Spirer, Chief Executive Officer of J.S. Held. “We are laser-focused on building highly integrated teams that combine technical, financial, and legal insight. This approach enables us to support both in-house and outside counsel with the depth, precision, and coordination required to address the evolving demands of AI-related litigation.”

J.S. Held’s investment in cross-disciplinary capabilities reflects its long-term commitment to delivering scalable, high-impact solutions in areas where the stakes are greatest.

J.S. Held AI Disputes Monitor – Q1 2026 Update

The Q1 2026 update of the J.S. Held AI Disputes Monitor reveals a sharp rise in litigation, particularly in the insurance sector.  Multiple lawsuits filed across the United States in early 2026 indicate growing scrutiny of AI-driven decision-making in claims processing and policy coverage, particularly within property and casualty insurance.

A total of 31 AI-related lawsuits were filed in Q1, marking a 46% increase over the average quarterly rate in 2025. At this pace, 2026 is projected to exceed the previous year’s total by nearly 50 percent.

The first-quarter 2026 snapshot underscores the accelerating pace of AI-related disputes and the growing demand for expert insight into the technical, financial, and legal dimensions of algorithmic decision-making.

To explore the full set of findings, download the latest edition of the J.S. Held AI Disputes Monitor.

About J.S. Held

J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

More than 1,500 professionals serve organizations across six continents, including 84% of the Global 200 Law Firms, 75% of the Forbes Top 20 Insurance Companies (90% of the NAIC Top 50 Property & Casualty Insurers), and 71% of Fortune 100 Companies.

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice.  Securities offered through PM Securities, LLC, d/b/a Phoenix IB or Ocean Tomo Investments, a part of J.S. Held, member FINRA/SIPC.  All rights reserved.

Contact:

Kristi L. Stathis | Global Public Relations | +1 786 833 4864 | Kristi.Stathis@jsheld.com 

Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care.

PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ — Today, the National Comprehensive Cancer Network^® (NCCN^®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of Nancy L. Lewis, MD, MBS, FACP, as new Chief Scientific Officer (CSO).

Nancy L. Lewis, MD, MBS, FACP, Named New Chief Scientific Officer for National Comprehensive Cancer Network (NCCN). Learn more at NCCN.org.

Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies. She most recently served as Senior Clinical Program Leader for Novartis Pharmaceuticals, after several years as an Associate Professor for various prestigious academic cancer centers. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. Dr. Lewis completed residency at the University of Rochester and Fellowship at Fox Chase Cancer Center—one of NCCN’s founding Member Institutions.

“This is a pivotal time for cancer research; there are many successes to build on yet so much still to do. Dr. Lewis is the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer,” said Crystal S. Denlinger, MD, CEO, NCCN. “She will be an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world.”

Dr. Lewis has previously been honored with awards from some of the foremost cancer organizations across the country, including the American Association for Cancer Research (AACR), The American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS).

As CSO, Dr. Lewis will assist in the NCCN Oncology Research Program (ORP) as well as key aspects of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and NCCN Guidelines for Patients^®. She will have oversight of the NCCN Biomarkers Compendium^®; NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Dr. Lewis will also assist with NCCN’s Continuing Medical Education Program and with relevant global and policy initiatives.

“I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy of advancing high‑quality cancer care,” said Dr. Lewis. “I look forward to working with NCCN’s exceptional collaborators to tackle emerging challenges and drive innovative solutions that improve the lives of patients everywhere.”

Dr. Lewis will succeed Dr. Denlinger who previously held the position of CSO before becoming CEO for the organization. Dr. Lewis will assume her new role in May 2026.  

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network^® (NCCN^®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients^® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation^®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org